ABC | Volume 114, Nº6, June 2020

Case Report Ritt et al. COVID-19 and cardiac collateral damage Arq Bras Cardiol. 2020; 114(6):1172-1075 1. Ibanez B, James S, Agewall S, Antunes M, Ducci CB, Alida HB, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J . 2018;39(2):119-77. 2. Avezum Junior Á, Feldman A, Carvalho ACDC, Sousa ACC, Mansur AP, Bozza AEZ, et al. V Diretriz da Sociedade Brasileira de Cardiologia sobre Tratamento do InfartoAgudo doMiocárdio comSupradesnível doSegmento ST. Arq Bras Cardiol . 2015;105(2):1-105. 3. Driggin E,MadhavanMV, Bikdeli B, Chuich T, Laracy J,ZoccaiGB,et al. et al. CardiovascularConsiderations forPatients,HealthCareWorkers,andHealth Systems During the Coronavirus Disease 2019 (COVID-19) Pandemic. J Am Coll Cardiol . 2020;2019. 4. Zeng J, Huang J, Pan L. How to balance acute myocardial infarction and COVID-19: the protocols from Sichuan Provincial People’s Hospital. Intensive Care Med . 2020;75(18):2352-371. 5. Nguyen JL, Yang W, Ito K, Matte TD, Shaman J, Kinney PL. Seasonal influenza infections and cardiovascular disease mortality. JAMA Cardiol . 2016;1(3):274-81. 6. BonowRO, FonarowGC, O’Gara PT, Yancy CW. Association of Coronavirus Disease 2019 (COVID-19) With Myocardial Injury and Mortality. JAMA Cardiol . 2020;323(11):1061-9. 7. Rodríguez-leor O, López-palop R, Serrador A, Martin-Moreiras J, Rumoroso JR, Perez de Prado A. Impacto de la pandemia de COVID-19 sobre la actividad asistencial en cardiología intervencionista en España.REC Interv Cardiol.2020;82-9. 8. Tam C-CF, Cheung K-S, Lam S,wang A, Yung A, Sza M, et al. Impact of Coronavirus Disease 2019 (COVID-19) Outbreak on ST-Segment–Elevation Myocardial Infarction Care in Hong Kong, China. Circ Cardiovasc Qual Outcomes . 2020;13(4):e006631,2020 04. 9. Alharbi FF, Souverein PC, DeGroot MC, Maitland-VanDer Zee AH, De Boer A, Klungel OH. Risk of acute myocardial infarction after discontinuation of antihypertensive agents: A case-control study. J Hum Hypertens . 2017;31(8):537-44. 10. Fang L, Karakiulakis G, RothM. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med . 2020;8(4):e21. 11. Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosniban AKB, Tallant A, et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation . 2005;111(20):2605-10. 12. Ramchand J, Patel SK, Srivastava PM, Farouque O, Burrell LM. Elevated plasmaangiotensinconvertingenzyme2activity isan independentpredictor of major adverse cardiac events in patients with obstructive coronary artery disease. PLoS One . 2018;13(6):1-11. 13. Bavishi C, Maddox TM, Messerli FH. Coronavirus Disease 2019 (COVID-19) Infection and Renin Angiotensin System Blockers. JAMA Cardiol . 2020;19(8):1965-74. 14. Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med . 2005;11(8):875-9. References This is an open-access article distributed under the terms of the Creative Commons Attribution License 1075